Cargando…
Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
OBJECTIVE: This trial evaluated the short-term safety and tolerability, steady-state pharmacokinetics, and preliminary efficacy of brivaracetam oral solution in children aged 1 month to < 16 years with epilepsy. METHODS: This was a phase IIa, open-label, single-arm, fixed three-step dose escalati...
Autores principales: | Liu, Edwin, Dilley, Deanne, McDonough, Belinda, Stockis, Armel, Daniels, Tony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682562/ https://www.ncbi.nlm.nih.gov/pubmed/31250322 http://dx.doi.org/10.1007/s40272-019-00332-y |
Ejemplares similares
-
Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years
por: Schoemaker, Rik, et al.
Publicado: (2017) -
Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial
por: Farkas, Mark Kristof, et al.
Publicado: (2022) -
Extrapolation of a Brivaracetam Exposure–Response Model from Adults to Children with Focal Seizures
por: Schoemaker, Rik, et al.
Publicado: (2017) -
Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50‐mg Film‐Coated Tablet
por: Otoul, Christian, et al.
Publicado: (2016) -
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)